POSB342 Time Until Definitive Deterioration (TUDD) in Patient Reported Outcomes (PROS) in a Phase 3 Trial for Ripretinib in 4L Patients with Gastrointestinal Stromal Tumour (GIST)
Abstract
Authors
C Becker B Harrow MC Heinrich P Schöffski C Serrano B Vincenzi JY BLAY